The Effect of Vitamin D Supplementation on the Outcome of Treatment with Bevacizumab in Diabetic Macular Edema: a Randomized Clinical Trial

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2022 May 11

PMID 35543853

Authors

Sahba Fekri

Masoud Soheilian

Sepehr Roozdar

Seyed-Hossein Abtahi

Hosein Nouri

Affiliations

Soon will be listed here.

Abstract

Purpose: Concomitant vitamin D deficiency (VDD) is speculated to aggravate diabetic macular edema (DME). We aimed to determine the effect of hypovitaminosis D correction on the outcome of treatment with intravitreal bevacizumab (IVB) in DME eyes.

Methods: In this randomized clinical trial, 83 eyes of 83 patients with DME were recruited and divided into three groups: normal vitamin D levels + IVB administration (Group 1), vitamin D insufficient/deficient + IVB administration (Group 2), and vitamin D insufficient/deficient + IVB administration + oral vitamin D supplementation (Group 3). Participants were followed for 6 months after the intervention. Visual (corrected distance visual acuity, CDVA) and anatomical (central macular thickness, CMT) outcomes of intervention were evaluated 1, 3, and 6 months after three monthly loading doses of IVB were given. Serum vitamin D levels were measured 1 and 6 months after the third IVB administration.

Results: A total of 29, 26, and 28 eyes were enrolled in groups 1, 2, and 3, respectively. In months 1, 3, and 6, after the three basic loading doses of IVB, visual acuity and CMT improved in all three groups, but improvements (both functional and anatomical) in groups 1 and 3 in month 6 were more significant than in group 2 (mean CDVA LogMAR changes: - 0.18 ± 0.03, - 0.14 ± 0.05, and - 0.2 ± 0.06; mean CMT reductions: - 82.24 ± 11.43, - 66.62 ± 14.34, and - 86.14 ± 18.36, in groups 1, 2, and 3, respectively; p < 0.001). The mean number of IVB injections during follow-up was 5.33 (range 4-7), which did not differ between the groups.

Conclusion: Correction of vitamin D deficiency in DME patients with type 2 diabetes and vitamin D deficiency, in addition to IVB injections, may play a role in improving CDVA and CMT. However, this beneficial effect seems to be delayed by several months.

Trial Registration: Iranian Registry of Clinical Trials (IRCT), IRCT20200407046978N1, registered on April 11, 2020, retrospectively registered ( https://en.irct.ir/trial/46999 ).

Citing Articles

The Role of Diet and Oral Supplementation for the Management of Diabetic Retinopathy and Diabetic Macular Edema: A Narrative Review.

DAngelo A, Lixi F, Vitiello L, Gagliardi V, Pellegrino A, Giannaccare G Biomed Res Int. 2025; 2025:6654976.

PMID: 40041571 PMC: 11876532. DOI: 10.1155/bmri/6654976.

Vitamin D Deficiency as a Risk Factor for Diabetic Retinopathy: A Systematic Review and Meta-Analysis.

Petrea C, Ghenciu L, Iacob R, Stoicescu E, Sandesc D Biomedicines. 2025; 13(1).

PMID: 39857652 PMC: 11762121. DOI: 10.3390/biomedicines13010068.

Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights.

Al Sakini A, Hamid A, Alkhuzaie Z, Al-Aish S, Al-Zubaidi S, Tayem A Int J Retina Vitreous. 2024; 10(1):83.

PMID: 39468614 PMC: 11514910. DOI: 10.1186/s40942-024-00603-y.

The Role of Vitamin D3 in Ocular Diseases.

Mrugacz M, Pienczykowska K, Bryl A Nutrients. 2024; 16(12).

PMID: 38931233 PMC: 11206323. DOI: 10.3390/nu16121878.

Effects of vitamin family members on insulin resistance and diabetes complications.

Chen H, Wang M, Zou D, Liang G, Yang S World J Diabetes. 2024; 15(3):568-571.

PMID: 38591081 PMC: 10999036. DOI: 10.4239/wjd.v15.i3.568.

References

Sharma T . Evolving role of anti-VEGF for diabetic macular oedema: from clinical trials to real life. Eye (Lond). 2019; 34(3):415-417. PMC: 7055591. DOI: 10.1038/s41433-019-0590-0. View

Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R . Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016; 2016:2156273. PMC: 5059543. DOI: 10.1155/2016/2156273. View

Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A . Mechanisms of macular edema: Beyond the surface. Prog Retin Eye Res. 2017; 63:20-68. DOI: 10.1016/j.preteyeres.2017.10.006. View

Hu Z, Chen J, Sun X, Wang L, Wang A . Efficacy of vitamin D supplementation on glycemic control in type 2 diabetes patients: A meta-analysis of interventional studies. Medicine (Baltimore). 2019; 98(14):e14970. PMC: 6456062. DOI: 10.1097/MD.0000000000014970. View

Chiang K, Sun C, Chen M, Huang C, Hsu J, Yeh T . MART-10, the new brand of 1α,25(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro. J Steroid Biochem Mol Biol. 2015; 155(Pt A):26-34. DOI: 10.1016/j.jsbmb.2015.09.022. View

Alcubierre N, Valls J, Rubinat E, Cao G, Esquerda A, Traveset A . Vitamin D Deficiency Is Associated with the Presence and Severity of Diabetic Retinopathy in Type 2 Diabetes Mellitus. J Diabetes Res. 2015; 2015:374178. PMC: 4452859. DOI: 10.1155/2015/374178. View

Schulz K, Altman D, Moher D . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010; 11:32. PMC: 2857832. DOI: 10.1186/1745-6215-11-32. View

Furigay P, Swamy N . Anti-endothelial properties of 1,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of calcitriol. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):427-31. DOI: 10.1016/j.jsbmb.2004.03.011. View

Mantell D, Owens P, Bundred N, Mawer E, Canfield A . 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000; 87(3):214-20. DOI: 10.1161/01.res.87.3.214. View

10.

Merrigan S, Kennedy B . Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dre-miR-21 and VEGF. Br J Pharmacol. 2017; 174(16):2636-2651. PMC: 5522998. DOI: 10.1111/bph.13875. View

11.

Albert D, Scheef E, Wang S, Mehraein F, Darjatmoko S, Sorenson C . Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci. 2007; 48(5):2327-34. DOI: 10.1167/iovs.06-1210. View

12.

Taverna M, Selam J, Slama G . Association between a protein polymorphism in the start codon of the vitamin D receptor gene and severe diabetic retinopathy in C-peptide-negative type 1 diabetes. J Clin Endocrinol Metab. 2005; 90(8):4803-8. DOI: 10.1210/jc.2004-2407. View

13.

Varma R, Bressler N, Doan Q, Gleeson M, Danese M, Bower J . Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014; 132(11):1334-40. PMC: 4576994. DOI: 10.1001/jamaophthalmol.2014.2854. View

14.

Zhang J, Upala S, Sanguankeo A . Relationship between vitamin D deficiency and diabetic retinopathy: a meta-analysis. Can J Ophthalmol. 2017; 52(2):219-224. DOI: 10.1016/j.jcjo.2016.10.004. View

15.

Wilkinson C, Ferris 3rd F, Klein R, Lee P, Agardh C, Davis M . Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110(9):1677-82. DOI: 10.1016/S0161-6420(03)00475-5. View

16.

Klaassen I, van Noorden C, Schlingemann R . Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013; 34:19-48. DOI: 10.1016/j.preteyeres.2013.02.001. View

17.

Mazidi M, Karimi E, Rezaie P, Vatanparast H . The impact of vitamin D supplement intake on vascular endothelial function; a systematic review and meta-analysis of randomized controlled trials. Food Nutr Res. 2017; 61(1):1273574. PMC: 5404423. DOI: 10.1080/16546628.2016.1273574. View

18.

Aksoy H, Akcay F, Kurtul N, Baykal O, Avci B . Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem. 2000; 33(1):47-51. DOI: 10.1016/s0009-9120(99)00085-5. View

19.

Arima M, Nakao S, Yamaguchi M, Feng H, Fujii Y, Shibata K . Claudin-5 Redistribution Induced by Inflammation Leads to Anti-VEGF-Resistant Diabetic Macular Edema. Diabetes. 2020; 69(5):981-999. DOI: 10.2337/db19-1121. View

20.

Karimi S, Movafaghi V, Arabi A, Shahraki T, Safi S . Effects of Oral Vitamin D Supplement Therapy on Clinical Outcomes of Intravitreal Bevacizumab in Diabetic Macular Edema. J Ophthalmic Vis Res. 2021; 16(1):34-41. PMC: 7841288. DOI: 10.18502/jovr.v16i1.8249. View